A roadmap to a thriving industrial biotechnology sector in Europe.

Industrial Biotechnology-derived products are projected to offer 5 significant potential for overcoming many of the socio-economic and environmental challenges facing the EU today.

Spotlight

Medigene AG

Medigene is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with focus on haematological malignancies.

OTHER WHITEPAPERS
news image

Early engagement and regulatory considerationsfor biotech

whitePaper | May 10, 2022

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines

Read More
news image

Validation of ICON™ Automated Cell Counting and Viability Assay

whitePaper | August 10, 2022

Determination of cell viability and concentration using trypan blue exclusion is essential for biotherapeutic workflows, enabling optimisation of protocols, monitoring of changes to the culture environment, and selection of the best clones for culture progression.

Read More
news image

Advancing Diversity in Clinical Development through Cross-Stakeholder Commitment and Action

whitePaper | November 10, 2022

The call for achieving representative diversity in clinical trials and development programs is not new and indeed dates back more than five decades in the United States but has been amplified over the course of the COVID-19

Read More
news image

70 years of wood modifcation with fungi

whitePaper | March 18, 2022

Fungi are usually seen by the wood used only as destroyers or parasites. Material infestation should be avoided as far as possible for wood preservation reasons.

Read More
news image

Eliminate Noisy Oxygen Measurements in Bioreactors

whitePaper | March 27, 2023

Controlling the dissolved oxygen level in fermentation vessels and bioreactors is vital to maximizing production yield and ensuring high end-product quality.

Read More
news image

Biopharmaceutical Sector

whitePaper | May 29, 2023

tronger than expected US inflation and a bump in consumer spending have fuelled worldwide expectations that interest rates will go higher, as predictions about future monetary policy rapidly shift.

Read More

Spotlight

Medigene AG

Medigene is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with focus on haematological malignancies.

Events